Quick Answer: Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce natural growth hormone, which then reduces visceral fat by enhancing lipolysis and fat metabolism, particularly in patients with HIV-associated lipodystrophy.
Tesamorelin works by binding to growth hormone-releasing hormone receptors on your pituitary gland, triggering a cascade that makes your body produce more natural growth hormone—which then tells your fat cells, especially the stubborn visceral fat around your organs, to break down and release stored energy. Unlike injecting growth hormone directly, which shuts down your body's own production and floods your system with hormone, tesamorelin works within your existing feedback loops—your pituitary still calls the shots, just with a stronger signal. The result? Clinical trials show visceral fat drops by 15-18% over six months while your body maintains its natural regulatory control, meaning fewer side effects and a more sustainable approach to fat loss than direct hormone replacement[2][32].
This mechanism matters because visceral fat—the metabolically active fat wrapped around your liver, intestines, and other organs—responds differently to hormones than the subcutaneous fat you can pinch. Tesamorelin's targeted approach explains why guys see their waistlines shrink while arm and leg fat barely changes, and why the FDA approved it specifically for HIV patients dealing with treatment-related belly fat accumulation[9][32]. Here's exactly how this peptide works from the molecular level to the changes you'll actually notice.
What Is Tesamorelin and How Does It Differ from Direct Growth Hormone
Tesamorelin is a synthetic 44-amino acid peptide that mimics your body's natural growth hormone-releasing hormone (GHRH), which your hypothalamus produces to signal your pituitary gland[2][9]. Think of it as a molecular impersonator—it looks enough like the real thing that your pituitary receptors can't tell the difference, but with strategic modifications that make it more stable in your bloodstream than native GHRH. The key structural enhancement involves changes to the N-terminal portion of the molecule, which protect it from rapid enzymatic breakdown and extend its functional window to about 26-38 minutes—long enough to trigger hormone release but short enough to preserve your body's natural circadian rhythm of growth hormone secretion[2][8].
The fundamental difference between tesamorelin and direct growth hormone therapy comes down to control. When you inject recombinant human growth hormone (rhGH), you're bypassing your body's regulatory system entirely—flooding your bloodstream with exogenous hormone regardless of what your pituitary wants to do. This shuts down your natural production through negative feedback, potentially creating dependency and pushing IGF-1 (insulin-like growth factor-1) to supraphysiological levels that increase risks of glucose intolerance, carpal tunnel syndrome, and theoretically malignancy[8][16]. Tesamorelin keeps your pituitary in the driver's seat. Your body still responds to its own feedback signals, still regulates hormone release based on metabolic needs, and maintains more physiological IGF-1 levels. This preservation of normal endocrine function translates to a lower adverse event burden and less metabolic disruption over time[1][2].
The Molecular Mechanism: How Tesamorelin Stimulates the Pituitary Gland
When you inject tesamorelin subcutaneously, it enters your bloodstream and travels to your anterior pituitary gland, where it binds to GHRH receptors on specialized cells called somatotrophs[1][8]. These receptors are G-protein coupled receptors—the same receptor family responsible for everything from adrenaline responses to opioid effects—which means binding triggers a cascade of intracellular events rather than a simple on-off switch. Specifically, tesamorelin binding activates adenylyl cyclase, an enzyme that converts ATP into cyclic AMP (cAMP), which then activates protein kinase A and ultimately promotes both the synthesis and secretion of growth hormone from storage granules within the somatotroph cells[8].
This mechanism matters because it means your pituitary retains its ability to regulate hormone release. If you've eaten recently and insulin levels are elevated, or if you're stressed and cortisol is high, these signals can still modulate the pituitary's response to tesamorelin—your body's feedback loops remain functional[1]. The growth hormone released enters systemic circulation and acts on multiple tissue types: liver cells (hepatocytes) where it stimulates IGF-1 production, fat cells (adipocytes) where it promotes lipolysis, muscle cells (myocytes) where it supports protein synthesis, and bone cells (osteoblasts) where it influences remodeling[2][8]. IGF-1 production, particularly in the liver, serves as both a biomarker of tesamorelin's effectiveness and a mediator of many growth hormone effects—it's the molecule doing much of the heavy lifting when it comes to metabolic improvements[2][8].
The timing of this response is faster than you might expect for the downstream metabolic effects. IGF-1 levels start climbing within days of your first injection, with concentrations more than doubling within the first two weeks of daily tesamorelin use[20]. Peak plasma tesamorelin concentration (Cmax) actually decreases slightly by day 14 compared to day 1, but IGF-1 continues rising, demonstrating that the biological effects outlast the peptide's presence in your bloodstream[20]. This pharmacokinetic pattern reflects both the drug's short half-life and the sustained downstream signaling it triggers through growth hormone and IGF-1.
Growth Hormone Release and Its Effects on Fat Metabolism
Growth hormone's effects on fat metabolism represent one of the most clinically significant aspects of tesamorelin therapy, particularly for guys dealing with stubborn abdominal fat that won't respond to diet and exercise alone. At the cellular level, growth hormone binds to receptors on adipocytes and activates hormone-sensitive lipase (HSL), the enzyme responsible for breaking down stored triglycerides into free fatty acids and glycerol that can enter circulation and be oxidized for energy[2]. This lipolytic effect is dose-dependent and sustained as long as growth hormone levels remain elevated, which in tesamorelin's case means as long as you continue daily injections to maintain stimulation of pituitary secretion.
The metabolic shift extends beyond simple fat breakdown. Growth hormone promotes increased use of fatty acids for energy production while simultaneously having a glucose-sparing effect—your tissues preferentially burn fat instead of carbohydrates when growth hormone levels are elevated[2]. This metabolic switch has implications both positive (enhanced fat oxidation, improved body composition) and potentially concerning (reduced insulin sensitivity in some individuals, though this effect varies considerably between patients). In clinical trials, the net effect was generally favorable: total triglycerides decreased by 50 mg/dL in tesamorelin-treated patients compared to a 9 mg/dL increase in placebo recipients, and the ratio of total cholesterol to HDL cholesterol improved significantly[32].
The IGF-1 produced in response to growth hormone amplifies and sustains these metabolic effects. IGF-1 independently promotes glucose uptake in muscle tissue, supports protein synthesis, and inhibits programmed cell death in various tissues[2]. The combination of direct growth hormone effects and IGF-1-mediated actions creates a sustained metabolic environment favoring fat oxidation and lean mass preservation. In practical terms, this means you're not just losing fat—you're shifting your body's preferred fuel source and potentially improving muscle quality at the same time. Studies in HIV patients showed that trunk muscle density increased significantly across all four major truncal muscle groups in tesamorelin-treated individuals, with the rectus abdominis showing the largest gains[18].
Tesamorelin's Impact on Visceral Adipose Tissue Reduction
The most remarkable aspect of tesamorelin's mechanism is its preferential effect on visceral adipose tissue (VAT)—the metabolically active fat wrapped around your abdominal organs—compared to subcutaneous fat[9][32]. This selectivity isn't fully understood at the molecular level, but research suggests it involves differential expression of growth hormone receptors in visceral versus subcutaneous adipose depots, combined with enhanced lipolytic responsiveness of visceral adipocytes to growth hormone signaling[24]. Visceral fat cells appear to have higher concentrations of beta-adrenergic receptors and lower concentrations of alpha-adrenergic receptors, making them more responsive to lipolytic signals including those triggered by growth hormone[24].
Clinical trial results demonstrate this selectivity consistently. In the primary Phase 3 trial, visceral adipose tissue decreased by 15.2% in tesamorelin-treated patients compared to a 5.0% increase in placebo recipients over 26 weeks—a highly statistically significant difference representing about 24 cm² reduction on cross-sectional CT imaging[32][44]. Subcutaneous fat, measured in the same patients using the same imaging techniques, showed minimal changes in either direction. This pattern continued through 52 weeks of treatment, with sustained visceral fat reductions of approximately 18% relative to baseline while subcutaneous adipose tissue remained essentially unchanged[19][44].
The clinical significance extends beyond cosmetic improvements. Visceral adiposity associates strongly with metabolic syndrome, insulin resistance, cardiovascular disease risk, and systemic inflammation—it's the fat that actually threatens your health rather than just your appearance[13]. By specifically targeting this depot, tesamorelin addresses metabolic risk factors rather than just reducing total body weight. Moreover, research shows tesamorelin improves visceral adipose tissue quality, measured as increased fat density independent of volume changes, which correlates with increased adiponectin production[24]. Adiponectin is a beneficial hormone secreted by fat tissue that improves insulin sensitivity and reduces inflammation—higher levels mean healthier metabolic function even before considering fat volume reduction[24].
The Role of IGF-1 in Tesamorelin's Mechanism of Action
IGF-1 serves as both a biomarker of tesamorelin's effectiveness and a direct mediator of many therapeutic effects, making it central to understanding how this therapy works[2][8]. When growth hormone reaches the liver, it stimulates hepatocytes to produce and secrete IGF-1, which then circulates bound to IGF-binding proteins that modulate its activity and extend its half-life[2]. In tesamorelin-treated patients, IGF-1 levels increase by approximately 81% compared to baseline after 26 weeks of treatment—a substantial elevation that remains within the upper end of the physiological range seen in healthy young adults[32].
IGF-1's metabolic effects complement and amplify those of growth hormone itself. In adipose tissue, IGF-1 promotes differentiation of preadipocytes into mature fat cells capable of proper metabolic function—a process called adipogenesis that, counterintuitively, can improve metabolic health by creating "healthy" fat cells that properly store and release lipids rather than dysfunctional cells that contribute to insulin resistance[2]. In muscle tissue, IGF-1 stimulates protein synthesis, promotes satellite cell proliferation and differentiation (critical for muscle repair and growth), and inhibits protein breakdown through suppression of ubiquitin-proteasome pathways[2]. These anabolic effects explain the improvements in muscle density and lean muscle area observed in tesamorelin clinical trials[18].
The cardiovascular and metabolic implications of elevated IGF-1 remain incompletely characterized and somewhat controversial. On one hand, IGF-1 improves insulin sensitivity in muscle tissue, promotes glucose uptake, and supports endothelial function—all beneficial effects[2]. On the other hand, persistently elevated IGF-1 raises theoretical concerns about stimulation of cell proliferation that could promote malignancy in patients with preexisting but undetected cancerous cells, though clinical trial data have not documented increased cancer incidence with tesamorelin use[5][44]. The FDA requires monitoring of IGF-1 levels during therapy, with consideration for dose reduction or discontinuation if levels exceed 3 standard deviations above age-adjusted means[5][38]. In clinical practice, most patients' IGF-1 elevations remain within acceptable ranges, and the monitoring serves primarily as a safety check rather than a common reason for treatment modification.
Clinical Efficacy in HIV-Associated Lipodystrophy
Tesamorelin received FDA approval based on its demonstrated efficacy in HIV-infected patients with lipodystrophy—a condition characterized by redistribution of body fat that leads to increased visceral adiposity, metabolic dysfunction, and significant psychological distress related to altered body appearance[2][5]. The clinical trials establishing this efficacy enrolled over 800 HIV-positive patients with documented excess abdominal fat, randomizing them to receive either 2 mg daily subcutaneous tesamorelin or placebo for 26 weeks[32]. The results were unambiguous: visceral fat reductions of approximately 15-18% occurred in treated patients while placebo recipients gained visceral fat, and these improvements translated to measurable metabolic benefits including triglyceride reductions and improved lipid profiles[32].
The psychological benefits proved equally significant. Using validated body image assessment instruments, researchers documented that tesamorelin-treated patients reported substantially less distress regarding belly appearance and overall body appearance compared to placebo recipients—improvements that persisted through 52 weeks of continuous treatment but reversed when patients were switched to placebo[22]. The magnitude of improvement, measured as an 11.6-unit decrease in belly appearance distress scores at 26 weeks, exceeded the minimal clinically important difference defined for these instruments, indicating that patients perceived meaningful improvements in quality of life[22].
The durability of effects required continuous treatment. Extension phase data showed that patients who continued tesamorelin for 52 weeks maintained their visceral fat reductions, but those switched to placebo after the initial 26 weeks experienced rapid reaccumulation of fat, returning to near-baseline levels within several months[19][44]. This pattern establishes tesamorelin as a chronic therapy rather than a time-limited intervention—benefits persist only with ongoing use. For HIV patients facing lifetime antiretroviral therapy and its associated metabolic complications, this chronic treatment model aligns with their existing medication regimens, but it represents an important consideration for other populations considering off-label tesamorelin use[40].
Safety Profile and How the Body Responds to Treatment
Tesamorelin's safety profile reflects both its mechanism of action and the populations studied in clinical trials. The most common adverse effects relate directly to the subcutaneous injection route: injection site reactions including redness, itching, pain, and occasionally bruising occurred in about 25% of treated patients compared to 14% of placebo recipients[2][7]. These reactions are typically mild and manageable through systematic rotation of injection sites across different abdominal areas, avoiding the same location repeatedly[5]. More clinically significant adverse effects involve fluid retention and its musculoskeletal consequences—approximately 10-25% of patients experience edema, joint pain, muscle aches, or related symptoms[7][34]. Carpal tunnel syndrome, caused by fluid accumulation compressing the median nerve at the wrist, has been reported though it remains uncommon[7][33].
The glucose metabolism effects deserve particular attention. While tesamorelin generally maintains glycemic control in most patients, about 5% of treated individuals developed elevated hemoglobin A1C levels (≥6.5%) compared to 1% of placebo recipients, translating to a 3.3-fold increased hazard ratio for diabetes development[5]. This risk appears concentrated in patients with baseline metabolic dysfunction or impaired fasting glucose rather than representing a universal effect. Interestingly, studies specifically examining tesamorelin in type 2 diabetic patients found that 12 weeks of treatment did not alter insulin response or glycemic control despite significant IGF-1 elevations, suggesting that diabetes risk may be more nuanced than simple glucose intolerance[30]. Current clinical practice guidelines recommend periodic glucose monitoring in all tesamorelin-treated patients, with particular vigilance in those with metabolic syndrome risk factors[5][38].
Immunogenicity emerged as an interesting finding: between 50-56% of patients developed detectable anti-tesamorelin IgG antibodies during the first 26 weeks of treatment, with antibody titers decreasing after discontinuation[5][34]. Despite this high prevalence of antibody formation, the presence of anti-tesamorelin antibodies did not significantly impair treatment efficacy for visceral fat reduction or IGF-1response in pooled analyses[5][34]. This suggests that while the immune system recognizes tesamorelin as foreign, the antibodies formed don't neutralize its biological activity in most patients. Long-term safety data through 52 weeks showed that adverse event rates during the extension phase (weeks 27-52) remained comparable to the initial treatment period, with no serious adverse events deemed causally related to the study drug[19].
Comparison Tables
Tesamorelin vs Direct Growth Hormone Administration
| Feature | Tesamorelin | Direct GH Injection |
|---|---|---|
| Mechanism | Stimulates natural GH production via pituitary receptors | Replaces natural GH with synthetic hormone |
| Body's Natural Control | Maintains feedback loops and regulatory control | Shuts down body's own GH production |
| Visceral Fat Reduction | 15-18% over 6 months | Variable, often with more side effects |
| Side Effect Profile | Fewer side effects due to natural regulation | Higher risk of edema, joint pain, insulin resistance |
| Sustainability | More sustainable long-term approach | Often requires cycling or dose adjustments |
| Pituitary Function | Preserves natural pituitary signaling | Suppresses natural pituitary GH release |
Fat Types and Their Response to Tesamorelin
| Fat Type | Location | Response to Tesamorelin | Metabolic Activity | Clinical Significance |
|---|---|---|---|---|
| Visceral Fat | Around organs (liver, intestines) | High response - primary target | Highly metabolically active | 15-18% reduction in 6 months |
| Subcutaneous Fat | Under skin (pinchable fat) | Lower response | Less metabolically active | Minimal to moderate reduction |
| Abdominal Visceral | Deep belly cavity | Strongest response | Releases inflammatory factors | Associated with metabolic syndrome |
| Organ-Associated | Wrapped around specific organs | High response | Interferes with organ function | Improves organ health markers |
How Tesamorelin's Mechanism Compares to Other Fat Loss Approaches
| Approach | Mechanism | Natural Hormone Balance | Visceral Fat Targeting | Regulatory Control | Long-term Safety |
|---|---|---|---|---|---|
| Tesamorelin | GHRH receptor stimulation | Preserved | Specific and strong | Body maintains control | Favorable profile |
| Direct GH | Hormone replacement | Disrupted | Moderate | External control | Higher risk |
| Diet/Exercise | Caloric deficit | Maintained | Non-specific | Natural | Safest |
| Liposuction | Physical removal | No effect | Can target visceral surgically | N/A | Surgical risks |
| GLP-1 Agonists | Appetite suppression | Maintained | Indirect via weight loss | Natural | Generally favorable |
References
- Tesamorelin: A Growth Hormone-Releasing Factor Analogue - Review of tesamorelin's mechanism as a GHRH analogue
- Growth Hormone-Releasing Hormone: Structure and Function - Study explaining GHRH receptor binding and signaling pathways
- Tesamorelin for Visceral Adiposity in HIV-Infected Patients - Clinical trial demonstrating tesamorelin's effects on abdominal fat reduction
- Growth Hormone Secretion and Pituitary Function - Study showing pituitary stimulation by GHRH analogues
- Physiological Actions of Growth Hormone on Metabolism - Review of growth hormone effects on lipid and glucose metabolism
- Tesamorelin Reduces Visceral Fat and Improves Metabolic Parameters - Study showing metabolic improvements with tesamorelin treatment
- Growth Hormone and Lipolysis Mechanisms - Research explaining growth hormone-mediated fat breakdown
- GHRH Analogues: Pharmacology and Clinical Applications - Overview of GHRH analogue pharmacodynamics and therapeutic uses
- Effects of Tesamorelin on Body Composition in HIV Lipodystrophy - Clinical trial data on body composition changes with tesamorelin
- Growth Hormone Secretagogues and Pulsatile GH Release - Study examining pulsatile growth hormone secretion patterns
- Insulin-Like Growth Factor-1: Biological Actions - Review of IGF-1 production and metabolic effects
- Tesamorelin Treatment: Safety and Efficacy Profile - Comprehensive analysis of tesamorelin's safety and therapeutic outcomes
- Growth Hormone Effects on Adipose Tissue - Study showing growth hormone's direct effects on fat tissue
- GHRH Receptor Signaling and Downstream Effects - Research on GHRH receptor activation and cellular signaling cascades
- Tesamorelin and Cardiovascular Risk Factors - Study examining tesamorelin's impact on cardiovascular markers
- Growth Hormone Axis Regulation and Feedback Mechanisms - Review of growth hormone regulation and homeostasis
- Metabolic Effects of Growth Hormone Therapy - Study on metabolic changes induced by growth hormone treatment
- Tesamorelin Pharmacokinetics and Pharmacodynamics - Research on tesamorelin absorption, distribution, and action
- Growth Hormone and Protein Metabolism - Study showing growth hormone effects on protein synthesis and muscle
- Long-Term Effects of Tesamorelin on Visceral Adipose Tissue - Long-term clinical trial data on sustained visceral fat reduction
Frequently Asked Questions
How long does it take for tesamorelin to start working?
Tesamorelin typically begins showing measurable effects on visceral adipose tissue within 3-6 months of daily treatment. The medication works by stimulating the pituitary gland to produce growth hormone, which then promotes lipolysis. Clinical trials demonstrated significant reductions in visceral fat after 26 weeks of continuous use. Individual response times may vary based on baseline visceral fat levels, dosing consistency, and metabolic factors. Patients should not expect immediate results, as the reduction in abdominal fat occurs gradually through sustained hormonal stimulation.
Does tesamorelin cause permanent fat loss or do you need continuous treatment?
Tesamorelin requires continuous treatment to maintain visceral fat reduction. Clinical studies show that when treatment is discontinued, visceral adipose tissue typically returns to near-baseline levels within several months. The medication works by ongoing stimulation of growth hormone release, not by permanently altering fat cell metabolism or number. Once the hormonal stimulus is removed, the body's fat distribution patterns gradually revert. Patients who stop treatment generally experience regrowth of visceral fat, though lifestyle modifications may help maintain some benefits. Long-term maintenance requires continued daily injections.
What is the difference between tesamorelin and growth hormone injections?
Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue that stimulates the pituitary gland to produce growth hormone naturally, while growth hormone injections provide synthetic GH directly. This key difference means tesamorelin preserves the body's natural pulsatile GH secretion pattern and feedback mechanisms, potentially reducing side effects. Tesamorelin's effects are more specific to fat reduction with less impact on glucose metabolism and insulin resistance compared to direct GH therapy. The indirect stimulation also maintains physiological regulation, whereas exogenous GH bypasses natural controls.
Can tesamorelin affect blood sugar levels?
Tesamorelin can affect glucose metabolism and blood sugar levels. By increasing growth hormone production, it may cause insulin resistance and elevated blood glucose in some patients. Clinical trials reported increased hemoglobin A1c levels and higher rates of glucose intolerance or diabetes development. Growth hormone has anti-insulin effects that can impair glucose uptake in tissues. Patients with diabetes or pre-diabetes require careful monitoring during treatment. Regular blood glucose and A1c testing is recommended, especially in the first months of therapy to detect any metabolic changes early.
How does tesamorelin specifically target visceral fat versus subcutaneous fat?
Tesamorelin doesn't directly target visceral fat specifically; rather, visceral adipose tissue appears more sensitive to growth hormone's lipolytic effects. Visceral fat has higher metabolic activity and more GH receptors compared to subcutaneous fat, making it more responsive to hormonal signals. The increased growth hormone from tesamorelin stimulates lipolysis throughout the body, but visceral adipocytes undergo greater mobilization. Additionally, visceral fat has better blood supply and different receptor profiles. Clinical trials consistently show preferential visceral fat reduction with minimal changes to subcutaneous fat, reflecting these biological differences in fat depot responsiveness.
What happens to growth hormone levels after stopping tesamorelin?
After discontinuing tesamorelin, growth hormone levels return to baseline within days to weeks. Since tesamorelin works by stimulating natural GH production rather than replacing it, there's no long-term suppression of the pituitary's ability to produce growth hormone. The body's hypothalamic-pituitary axis resumes its normal function once the external stimulus is removed. Unlike direct growth hormone therapy, which can suppress natural production, tesamorelin doesn't cause lasting hormonal disruption. Studies show no evidence of rebound suppression or permanent changes to endogenous GH secretion after treatment cessation.
Is tesamorelin safe for people without HIV-associated lipodystrophy?
Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy and hasn't been extensively studied or approved for other populations. While the mechanism of action would theoretically work similarly in non-HIV patients with excess visceral fat, safety and efficacy data are limited outside this indication. Off-label use occurs but lacks regulatory approval and comprehensive safety profiles. Potential risks include glucose intolerance, injection site reactions, and hormonal effects that may differ in populations without HIV-related metabolic changes. Anyone considering tesamorelin without HIV-lipodystrophy should consult healthcare providers about risks, benefits, and alternative evidence-based treatments.
How does tesamorelin compare to other treatments for abdominal fat?
Tesamorelin is unique in specifically reducing visceral (internal) abdominal fat through hormonal mechanisms, unlike most treatments that target subcutaneous fat. Diet and exercise reduce both fat types but require significant lifestyle changes. Liposuction only removes subcutaneous fat and cannot access visceral deposits. Other medications like metformin may help metabolic health but lack tesamorelin's targeted visceral fat reduction. GLP-1 agonists promote overall weight loss including some visceral fat reduction through different mechanisms. Tesamorelin's advantage is specific visceral adipose reduction in HIV-lipodystrophy, though it requires daily injections and ongoing treatment.
Does tesamorelin build muscle mass like growth hormone does?
Tesamorelin produces modest increases in lean body mass, but significantly less muscle growth than direct growth hormone therapy. While it stimulates GH production, the increases are more moderate and physiologic compared to pharmacologic GH doses. Clinical trials show small improvements in lean tissue, primarily from reduced fat mass rather than substantial muscle gain. The anabolic effects on muscle are limited because tesamorelin's primary action is lipolytic. Patients should not expect bodybuilding-type muscle gains. The medication is designed specifically for visceral fat reduction, not muscle enhancement or performance improvement.
What are the most common side effects and how does the mechanism explain them?
Common side effects include injection site reactions (redness, itching, pain), arthralgias, and peripheral edema, directly related to growth hormone's effects on tissues. Injection site reactions occur from local immune responses to the synthetic peptide. Joint pain and swelling result from GH-induced fluid retention and effects on connective tissue. Nausea and other gastrointestinal symptoms may relate to hormonal influences on metabolism. Some patients experience numbness or tingling from fluid retention affecting nerves. The glucose metabolism effects can cause elevated blood sugar. These side effects reflect growth hormone's systemic actions on multiple tissues beyond fat.
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any treatment.